Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
Initial public offering and listing on GEM
Announcement of offline preliminary placement results
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
hot tip
The application of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (hereinafter referred to as “Hualan vaccine” and “issuer”) for the initial public offering of 40.01 million RMB common shares (A shares) (hereinafter referred to as “this offering”) and listing on the gem has been examined and approved by the GEM Listing Committee of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”), It has been approved to register by China Securities Regulatory Commission (hereinafter referred to as “CSRC”) (zjxk [2022] No. 2).
The issuer negotiated with the sponsor (lead underwriter) Huatai United Securities Co., Ltd. (hereinafter referred to as “Huatai United Securities”, “sponsor (lead underwriter)” and “lead underwriter”) to determine that the number of shares issued this time is 40.01 million shares. The offering price is 56.88 yuan / share, which does not exceed the median and weighted average of offline investors’ quotations after excluding the highest quotation, as well as the Securities Investment Fund (hereinafter referred to as “public fund”) and the National Social Security Fund (hereinafter referred to as “social security fund”) established through public offering after excluding the highest quotation The lower of the median and weighted average quotation of the basic endowment insurance fund (hereinafter referred to as “pension”), the enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund (hereinafter referred to as “enterprise annuity”) and the insurance fund (hereinafter referred to as “insurance fund”) in accordance with the measures for the administration of the use of insurance funds, is 62.0000 yuan / share.
According to the issuing price, the relevant subsidiaries of the sponsor will not participate in the strategic placement. The strategic placement object of this issuance is only the special asset management plan of the issuer’s senior managers and core employees. The final number of strategic placement is 4001000 shares, accounting for 10.00% of this issuance. The difference between the initial number of strategic placements and the final number of strategic placements is 2000500 shares transferred back to offline issuance.
This offering will eventually adopt targeted placement to strategic investors (hereinafter referred to as “strategic placement”) Offline inquiry placement to qualified offline investors (hereinafter referred to as “offline issuance”) and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts in Shenzhen market (hereinafter referred to as “online issuance”).
After the callback of strategic placement and before the launch of online and offline callback mechanism, the initial number of offline issuance was 29207500 shares, accounting for 81.11% of the number of this issuance after deducting the final strategic placement, and the initial number of online issuance was 6801500 shares, accounting for 18.89% of the number of this issuance after deducting the final strategic placement. The total number of final offline and online issuance is 36009000 shares. The final number of online and offline issuance will be determined according to the online and offline callback.
According to the callback mechanism announced in the announcement of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. on initial public offering and listing on the gem (hereinafter referred to as the “issuance announcement”), since the initial effective subscription multiple on the Internet is 9611.90384 times, more than 100 times, the issuer and the main contractor decided to start the callback mechanism to adjust the scale of offline and online issuance, After deducting the final strategic placement, 20.00% (rounded up to an integral multiple of 500 shares, i.e. 7202000 shares) of the number of shares issued this time will be transferred back from offline to online.
After the callback mechanism was launched, the final number of shares issued offline was 22005500, accounting for 61.11% of the number of shares issued this time after deducting the final strategic placement, and the final number of shares issued online was 14003500, accounting for 38.89% of the number of shares issued this time after deducting the final strategic placement. After the call back, the winning rate of this online issuance is 0.0214201484%, and the effective subscription multiple is 4668.50173 times.
Investors are kindly requested to focus on the issuance process, payment and other links of this issuance, as follows:
1. According to the announcement on the results of initial public offering and initial offline placement of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. listed on the gem, the offline allocated investors shall timely and fully pay the subscription funds for new shares before 16:00 on February 10 (T + 2) 2022 according to the finally determined issuance price and initial placement quantity.
The subscription funds shall be paid in full within the specified time. If the subscription funds are not paid in full within the specified time or as required, all the new shares allocated to the placing object shall be invalid. If the above-mentioned circumstances occur when multiple new shares are issued on the same day, all the placing objects are invalid. If different placing objects share bank accounts, if the subscription funds are insufficient, all the new shares allocated to the placing objects sharing bank accounts will be invalid. Offline investors are allocated multiple new shares on the same day. Please pay for each new share separately. The shares that offline investors give up to subscribe for are underwritten by the sponsor (lead underwriter).
2. Among the stocks issued this time, the stocks issued online have no circulation restrictions and limited sales period arrangements, and can be circulated from the date when the stocks issued this time are listed on the Shenzhen Stock Exchange.
The offline issuance part adopts the proportional sales restriction method, and the offline investors shall promise that the sales restriction period of 10% (rounded up) of the number of shares allocated to them is 6 months from the date of the issuer’s initial public offering and listing. That is, among the shares allocated to each placing object, 90% of the shares are unlocked and can be circulated from the date when the shares issued this time are listed and traded on the Shenzhen Stock Exchange; The lock-in period of 10% of the shares is 6 months, and the lock-in period starts from the date when the issued shares are listed and traded on the Shenzhen Stock Exchange.
When offline investors participate in the preliminary inquiry and quotation and offline purchase, they do not need to fill in the lock-in period arrangement for the placement object under their management. Once the quotation is made, it is deemed to accept the offline lock-in period arrangement disclosed in this announcement.
In terms of strategic placement, the issuer’s senior managers and core employees participated in the special asset management plan established by the strategic placement. The restricted period of the allocated shares is 12 months. The shares are restricted from the date of public offering in Shenzhen Stock Exchange.
3. When the total number of shares paid and subscribed by offline and online investors is less than 70% of the number of public offerings after deducting the final strategic placement, the issuer and the sponsor (lead underwriter) will suspend the issuance of new shares and disclose the reasons for the suspension and subsequent arrangements.
4. If the offline investor who provides effective quotation fails to participate in the subscription or the offline investor who obtains the preliminary placement fails to pay the subscription amount in time and in full, it will be deemed as a breach of contract and shall bear the liability for breach of contract. The recommendation institution (lead underwriter) shall report the breach of contract to the China Securities Association for the record. The number of violations of placing objects in various sectors of the stock market of Beijing stock exchange (hereinafter referred to as “Beijing stock exchange”), Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”) and Shenzhen Stock Exchange shall be calculated together.
During the period of being included in the restricted list, the placing object shall not participate in the offline inquiry and placement of relevant projects in all sectors of the stock market of Beijing stock exchange, Shanghai Stock Exchange and Shenzhen Stock Exchange.
5. Once this announcement is published, it shall be deemed to have served the notice of allocated payment to the offline investors participating in the offline subscription.
1、 Final result of strategic placement
The issuing price of this offering does not exceed the lower of the median and weighted average of offline investors’ quotations after excluding the highest quotation, and the median and weighted average of public funds, social security funds, pensions, enterprise annuity funds and insurance funds after excluding the highest quotation. Therefore, relevant subsidiaries of the recommendation institution do not need to participate in follow-up investment. According to the issuing price, the strategic placement object of this issuance is only the special asset management plan of the issuer’s senior managers and core employees. The final strategic placement number of this issuance is 4001000 shares, accounting for 10.00% of this issuance.
As of January 26, 2022 (T-4), strategic investors have paid their subscription funds in full and on time. according to
According to the relevant agreements in the strategic investor placement agreement for initial public offering of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. signed by the issuer and strategic investors, the strategic placement results of this issuance are determined as follows:
Serial no. Name of strategic investor number of allocated shares (shares) amount allocated (yuan) sales restriction period
1 Huatai Hualan vaccine home No. 1 gem 4001000 227576880.00 12-month ESOP collective asset management plan
Total 4001000 227576880.00-
Note: the restricted sale period shall be calculated from the date when the shares of this public offering are listed on the Shenzhen Stock Exchange
The recommendation institution (lead underwriter) will return the excess payment according to the original payment path of strategic investors before February 14, 2022 (T + 4).
2、 Offline issuance and subscription and preliminary placement results
(I) offline issuance and subscription
According to the measures for the administration of securities issuance and underwriting (CSRC order [No. 144]), the special provisions on the issuance and underwriting of initial public offerings on the gem (CSRC announcement [2021] No. 21), the implementation rules for the issuance and underwriting of initial public offerings on the gem of Shenzhen Stock exchange (revised in 2021) (SZS [2021] No. 919) Detailed rules for the implementation of offline issuance of initial public offerings in Shenzhen market (revised in 2020) (SZS [2020] No. 483), code for underwriting of initial public offerings under the registration system (zsxf [2021] No. 213), detailed rules for the management of offline investors in initial public offerings (zsxf [2018] No. 142) The sponsor (lead underwriter) has verified and confirmed the qualification of investors participating in offline subscription in accordance with the relevant provisions such as the management rules for offline investors of initial public offering under the registration system (Zhong Zheng Xie Fa [2021] No. 212) and the detailed rules for placement of initial public offering shares (Zhong Zheng Xie Fa [2018] No. 142). According to the effective subscription results finally received by the offline issuance electronic platform of Shenzhen Stock Exchange, the sponsor (lead underwriter) made the following statistics: the offline subscription of this issuance was completed on February 8 (t day) 2021. According to the requirements of the announcement, the number of investors participating in the issuance of 733.2 million shares under the announcement was confirmed to be valid.
(II) preliminary offline placement results
According to the offline placement principles and calculation methods published in the announcement on initial public offering and listing on gem of Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. (hereinafter referred to as the “announcement on preliminary inquiry and recommendation”), the issuer and the lead underwriter have made a preliminary placement of offline issued shares, and the preliminary placement results are as follows:
Proportion of effective subscription shares in the number of effective subscription allotments in the total number of (shares) purchased by various types of investors (10000 shares) issued offline
proportion
Class a investors 3715670 66.85% 15539114 70.61% 0.04181772%
Class B investors 27160 0.49% 112206 0.51% 0.04132108%
Class C investors 1815480 32.66% 6354180 28.88% 0.03500555%
Total 5558310 100.00% 22005500 100.00%——
Note: if the total is inconsistent with the mantissa of the sum of all itemized values, it is caused by rounding.
The remaining 2266 shares were allotted to the “Oriental new energy vehicle themed hybrid securities investment fund” in accordance with the offline placement principle announced in the preliminary inquiry and promotion announcement.
The above preliminary placement arrangements and results comply with the placement principles announced in the preliminary inquiry and promotion announcement. See the attached table for the preliminary placement of each final placement object.
3、 Contact information of sponsor (lead underwriter)
If offline investors have any questions about the offline preliminary placement results announced in this announcement, please contact the sponsor (lead underwriter) of this offering. The specific contact information is as follows:
Sponsor (lead underwriter): Huatai United Securities Co., Ltd
Contact: stock capital market department
Tel: 010-56839453
Contact email: [email protected].
Contact address: 6 / F, block a, Fengming international building, No. 22 Fengsheng Hutong, Xicheng District, Beijing
Issuer: Hualan Biological Engineering Inc(002007) vaccine Co., Ltd. sponsor (lead underwriter): Huatai United Securities Co., Ltd. February 10, 2022 (seal page)
Hualan Biological Engineering Inc(002007) vaccine Co., Ltd
